Polopiryna S awarded the “Teraz Polska” emblem
Polopiryna S – a Polpharma brand that has been trusted by Polish patients for many years – has made the winners list of the 28th edition of the “Teraz Polska” competition, run by the Polish Promotional Emblem Foundation. The brand won the award in the “Pharmaceutical Products” category.
Nearly 100 submissions were received for this year's edition. The jury chose 12 products, 10 services, 2 innovative projects and 2 municipalities. You are reading this article as part of a paid subscription. Your subscription is active
“We are very happy to have been awarded the “Teraz Polska” emblem. This prestigious title is recognised both in Poland and abroad. With such an endorsement, patients' trust in the product and the credibility of our company are bound to increase,” said Jerzy Ziemlicki, CHC Marketing Director, Polpharma SA.
For nearly 30 years, the “Teraz Polska” jury has been selecting the best Polish products, services, municipalities and projects – those that stand out in the market and serve as models for others to imitate, due to their high quality, technical merits or utilitarian value. After nearly a quarter of a century, the “Teraz Polska” emblem has become a brand in its own right. Its market power and high recognition strengthen competitive advantage and contribute to the market success of the products that bear it. The prestige of the “Teraz Polska” emblem is enhanced by the transparency of the procedures governing the competition, the objectivity, competence and independence of the experts and members of the jury, as well as the patronage of the President of the Republic of Poland.
Polopiryna S is one of the best-known medicines in Poland, and the most popular remedy for the cold and flu*. It has won many prestigious industry awards, including SUPERBRANDS 2010, 2009, 2005 – awarded to the strongest brands in Poland, TRUSTED BRANDS 2008 in the “remedies for the cold” category, and the ZŁOTY OTIS 2007 award for the most trusted products.
*Source: Polpharma data according to Omnibus PharmaExpert 12.2017, Nielsen 12.2017